Selinexor is a novel XPO1 inhibitor approved for patients with relapsed refractory multiple myeloma. When used as twice weekly dosing, selinexor is associated with significant toxicities, prohibiting its use in clinical practice. Newer combinations with other chemotherapeutic agents have evaluated less frequent and lower doses of Selinexor with aggressive supportive care. These novel combinations appear to have tolerable safety profiles while preserving drug efficacy, making Selinexor a reasonable option for patients with heavily pretreated relapsed refractory multiple myeloma.
Keywords: Clinical commentary; Relapsed refractory; Selinexor; multiple myeloma.
Copyright © 2021 Elsevier Inc. All rights reserved.